Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL30379944 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL8505 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL29362033 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL29375089 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL18159501 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL16685137 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL9166387 | 1.00 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL23704750 | 0.98 | KDM4E (1.00) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL1873501 | 0.98 | KDM4E (0.95) | KDM4EMAPTMAPK1TAAR1ADRA2A | |
| Dopamine SCHEMBL1668345 | 0.98 | KDM4E (0.95) | KDM4EMAPTMAPK1TAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108485389-B | Fluorine-containing polymer powder coating and preparation method and application thereof | 浙江巨化技术中心有限公司 | 2021-04-23 | — | — | CN | claimed |
| CN-105233770-B | A kind of preparation method of the wax phase change accumulation energy microcapsule of multilayer capsule skin | 广西壮族自治区化工研究院 | 2017-10-27 | — | — | CN | claimed |
| US-7776105-B2 | Oxidation color dyes comprising mixtures of 5,6-dihydroxyindoline-2-carboxylic acid or salts, bases and solvents; containing a melanin precursor prepared by a process including an oxidation step for converting, into the melanin precursor, a tyrosine or derivative with an enzyme or cell derived from fungi | KAO CORPORATION (JP) | 2010-08-17 | — | — | US | claimed |
| US-20100087622-A1 | Method of Synthesizing Acetonide-Protected Catechol-Containing Compounds and Intermediates Produced Therein | NORTHWESTERN UNIVERSITY (US) | 2010-04-08 | — | — | US | claimed |
| CN-118306985-A | Preparation method and application of nitrogen-doped graphene aerogel material | 内蒙古工业大学 | 2024-07-09 | — | — | CN | disclosed |
| US-20240194304-A1 | Prediction Method, Prediction Device, and Prediction Program for New Indication of Desired Known Drug or Equivalent Material Thereof | KARYDO THERAPEUTIX, INC. (JP) | 2024-06-13 | — | — | US | disclosed |
| EP-3689852-B1 | METHOD FOR PRODUCING DIHYDROXYINDOLES | KAO CORP (JP) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024058984-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11730021-B2 | Display device and method of manufacturing the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-20230241119-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASE, COMPRISING STEM CELL-DERIVED EXOSOME SURFACE-MODIFIED WITH COMPOUND CAPABLE OF BINDING TO DOPAMINE RECEPTORS OR L-AMINO ACID TRANSPORTERS | Research & Business Foundation Sungkyunkwan University (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230102580-A1 | ISOTOPICALLY-LABELLED TRAPIDIL DERIVATIVES | SINOPIA BIOSCIENCES, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220359630-A1 | DISPLAY DEVICE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-11-10 | — | — | US | disclosed |
| WO-2002018341-A9 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYST PROD INC (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001051659-A2 | BIALLELIC MARKERS DERIVED FROM GENOMIC REGIONS CARRYING GENES INVOLVED IN CENTRAL NERVOUS SYSTEM DISORDERS | GENSET (FR) | 2001-07-19 | — | — | WO | disclosed |
| EP-1045918-A1 | G PROTEIN-RELATED KINASE MUTANTS IN ESSENTIAL HYPERTENSION | Georgetown University Medical Center (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035279-A1 | G PROTEIN-RELATED KINASE MUTANTS IN ESSENTIAL HYPERTENSION | GEORGETOWN UNIVERSITY MEDICAL CENTER (US) | 1999-07-15 | — | — | WO | disclosed |
| US-5508311-A | Aliphatic propargylamines as selective MAO-B inhibitors and as neuroprotective agents | UNIVERSITY OF SASKATCHEWAN (CA) | 1996-04-16 | — | — | US | disclosed |
| EP-0573498-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992015551-A1 | ALIPHATIC PROPARGYLAMINES AS SELECTIVE MAO-B INHIBITORS AND AS NEUROPROTECTIVE AGENTS | UNIVERSITY OF SASKATCHEWAN (CA) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087622-A1 | Method of Synthesizing Acetonide-Protected Catechol-Containing Compounds and Intermediates Produced Therein | DBH, COMT, PAH | KDM4E 2054/4885MAPT 3973/4885MAPK1 2641/4885 |
| US-20230102580-A1 | ISOTOPICALLY-LABELLED TRAPIDIL DERIVATIVES | SNCA, PARK7, TRAP1 | KDM4E 4697/4885MAPT 101/4885MAPK1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.